%0 Journal Article %1 Mulla2012 %A Mulla, Sohail M. %A Scott, Ian A. %A Jackevicius, Cynthia A. %A You, John J. %A Guyatt, Gordon H. %D 2012 %J JAMA %K imported %N 24 %P 2605-11 %R 10.1001/2012.jama.11235 %T How to use a noninferiority trial: users' guides to the medical literature. %U http://www.ncbi.nlm.nih.gov/pubmed/23268519 http://jama.jamanetwork.com/article.aspx?doi=10.1001/2012.jama.11235 %V 308 %X Clinical investigators are increasingly testing treatments that have the primary benefit of decreased burden or harms relative to an existing standard. The goal of the resulting randomized trials--called noninferiority trials--is to establish that the novel treatment's effectiveness is not substantially less than the existing standard. Conclusions from these trials are, however, based on noninferiority thresholds specified by authors whose judgments may not coincide with those of patients and clinicians. This article highlights issues related to validity, interpretation, and applicability of results specific to noninferiority trials. Suboptimal administration of standard treatment or exclusive reliance on the analyze-as-randomized approach that is standard for conventional superiority trials may produce misleading results in noninferiority trials. Clinicians should judge whether the novel treatment's impact on effectiveness outcomes--the prime reason for wanting to prescribe it--is sufficiently close to that of standard treatment that they are comfortable substituting it for the existing standard. Trading off desirable and undesirable consequences is an individual decision: given the benefits of a novel treatment, some patients may perceive the uncertainty regarding a reduction in treatment effectiveness as acceptable while others may not.

@article{Mulla2012, abstract = {Clinical investigators are increasingly testing treatments that have the primary benefit of decreased burden or harms relative to an existing standard. The goal of the resulting randomized trials--called noninferiority trials--is to establish that the novel treatment's effectiveness is not substantially less than the existing standard. Conclusions from these trials are, however, based on noninferiority thresholds specified by authors whose judgments may not coincide with those of patients and clinicians. This article highlights issues related to validity, interpretation, and applicability of results specific to noninferiority trials. Suboptimal administration of standard treatment or exclusive reliance on the analyze-as-randomized approach that is standard for conventional superiority trials may produce misleading results in noninferiority trials. Clinicians should judge whether the novel treatment's impact on effectiveness outcomes--the prime reason for wanting to prescribe it--is sufficiently close to that of standard treatment that they are comfortable substituting it for the existing standard. Trading off desirable and undesirable consequences is an individual decision: given the benefits of a novel treatment, some patients may perceive the uncertainty regarding a reduction in treatment effectiveness as acceptable while others may not.}, added-at = {2023-02-03T11:44:35.000+0100}, author = {Mulla, Sohail M. and Scott, Ian A. and Jackevicius, Cynthia A. and You, John J. and Guyatt, Gordon H.}, biburl = {https://www.bibsonomy.org/bibtex/2a6beb76d5e331068910bab656a413f26/jepcastel}, doi = {10.1001/2012.jama.11235}, interhash = {b52c0d0ba7105786ba4eebac61802ed8}, intrahash = {a6beb76d5e331068910bab656a413f26}, issn = {1538-3598}, journal = {JAMA}, keywords = {imported}, month = {12}, note = {Tests d'equivalència; Critical appraisal; Introductori}, number = 24, pages = {2605-11}, pmid = {23268519}, timestamp = {2023-02-03T11:44:35.000+0100}, title = {How to use a noninferiority trial: users' guides to the medical literature.}, url = {http://www.ncbi.nlm.nih.gov/pubmed/23268519 http://jama.jamanetwork.com/article.aspx?doi=10.1001/2012.jama.11235}, volume = 308, year = 2012 }